Evidence map›Paper›PMID 30108960›Full record

ArticleMedChemComm2018

Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.

Haiyang Chen, Peiran Song, Yanyan Diao, Yongjia Hao, Dou Dou, Wanqi Wang, Xiaoyu Fang, Yanling Wang, Zhenjiang Zhao, Jian Ding and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedChemComm, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Haiyang ChenShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
Peiran SongDivision of Anti-tumor Pharmacology , State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , Shanghai 201203 , China . Email: hxie@jding.dhs.org.
Yanyan DiaoShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
Yongjia HaoShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
Dou DouShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
Wanqi WangShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
Xiaoyu FangShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
Yanling WangShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
Zhenjiang ZhaoShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
Jian DingDivision of Anti-tumor Pharmacology , State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , Shanghai 201203 , China . Email: hxie@jding.dhs.org.
Honglin LiShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.ORCID 0000-0003-2270-1900
Hua XieDivision of Anti-tumor Pharmacology , State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , Shanghai 201203 , China . Email: hxie@jding.dhs.org.
Yufang XuShanghai Key Laboratory of New Drug Design , State Key Laboratory of Bioreactor Engineering , School of Pharmacy , East China University of Science & Technology , Shanghai 200237 , China . Email: hlli@ecust.edu.cn ; Email: yfxu@ecust.edu.cn ; ; Tel: +86 21 64250213.
East China University of Science and Technology · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bruton's tyrosine kinase (BTK) plays a critical role in B cell receptor (BCR)-mediated signaling pathways responsible for the development and function of B cells, which makes it an attractive target for the treatment of many types of B-cell malignancies. Herein, a series of N5-substituted 6,7-dioxo-6,7-dihydropteridine-based, irreversible BTK inhibitors were reported with IC

Identifiers

PMID30108960
PMCPMC6071741
OpenAlexW2789392305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.